Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination.
Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort.
Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity.
What place for {blacktriangledown}cannabis extract in MS?
Quality of life in patients with multiple sclerosis in Republic of Srpska.
Quantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages.
Advances in the pharmacological and neurological treatment of patients with multiple sclerosis.
Cerebrospinal fluid ferritin-Unspecific and unsuitable for disease monitoring.
White matter disease: Longest follow-up of rituximab for neuromyelitis optica.
Posttranscriptional Gene Regulation of IL-17 by the RNA-Binding Protein HuR Is Required for Initiation of Experimental Autoimmune Encephalomyelitis.
Multiple sclerosis: Drug-enhanced remyelination in a multiple sclerosis model.
Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice.
Proceedings of the 6th Dubrovnik International Conference on Multiple Sclerosis, 10-12 May 2012, Dubrovnik, Croatia.
Generating induced pluripotent stem cells for multiple sclerosis therapy.
Poster Abstracts from the Fourth International Symposium on Gait and Balance in Multiple Sclerosis: The Role of CognitionCleveland Clinic • Cleveland, Ohio, USA • October 10 & 11, 2014.
Network collapse and cognitive impairment in multiple sclerosis.
Commentary on 'Disability outcome measures in multiple sclerosis clinical trials'
Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis.
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.
HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells.
Medicinal cannabis.
Reporting treatment outcomes in observational data: A fine balance.
Impaired social cognition in multiple sclerosis.
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis.
Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis.

Pages